Dana Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.8M | Sell |
46,136
-2,142
| -4% | -$125K | 0.08% | 259 |
|
|
2025
Q4 | $2.6M | Sell |
48,278
-42,334
| -47% | -$2.04M | 0.08% | 261 |
|
|
2025
Q3 | $4.09M | Sell |
90,612
-54,542
| -38% | -$2.55M | 0.12% | 194 |
|
|
2025
Q2 | $6.72M | Sell |
145,154
-15,229
| -9% | -$748K | 0.22% | 117 |
|
|
2025
Q1 | $9.78M | Sell |
160,383
-7,524
| -4% | -$439K | 0.35% | 63 |
|
|
2024
Q4 | $9.5M | Sell |
167,907
-309
| -0.2% | -$17.3K | 0.31% | 71 |
|
|
2024
Q3 | $8.7M | Buy |
168,216
+18,955
| +13% | +$889K | 0.29% | 88 |
|
|
2024
Q2 | $6.2M | Sell |
149,261
-181,821
| -55% | -$8.14M | 0.21% | 138 |
|
|
2024
Q1 | $18M | Buy |
331,082
+18,026
| +6% | +$918K | 0.6% | 37 |
|
|
2023
Q4 | $16.1M | Buy |
313,056
+93,221
| +42% | +$4.89M | 0.78% | 38 |
|
|
2023
Q3 | $12.8M | Sell |
219,835
-146,978
| -40% | -$9.01M | 0.65% | 49 |
|
|
2023
Q2 | $23.5M | Buy |
366,813
+4,617
| +1% | +$310K | 1.16% | 24 |
|
|
2023
Q1 | $25.1M | Buy |
362,196
+13,888
| +4% | +$980K | 1.28% | 16 |
|
|
2022
Q4 | $25.1M | Buy |
348,308
+23,611
| +7% | +$1.78M | 1.31% | 18 |
|
|
2022
Q3 | $23.1M | Buy |
324,697
+224,442
| +224% | +$16.3M | 1.31% | 16 |
|
|
2022
Q2 | $7.72M | Buy |
+100,255
| New | +$7.64M | 0.39% | 70 |
|
|
2021
Q3 | – | Sell |
-321,184
| Closed | -$21.5M | – | 319 |
|
|
2021
Q2 | $21.5M | Sell |
321,184
-1,908
| -0.6% | -$124K | 0.95% | 44 |
|
|
2021
Q1 | $20.4M | Buy |
323,092
+25,897
| +9% | +$1.61M | 0.94% | 44 |
|
|
2020
Q4 | $18.4M | Sell |
297,195
-1,703
| -0.6% | -$105K | 0.92% | 43 |
|
|
2020
Q3 | $18M | Sell |
298,898
-75,741
| -20% | -$4.56M | 0.98% | 42 |
|
|
2020
Q2 | $22M | Sell |
374,639
-72,442
| -16% | -$4.33M | 1.19% | 34 |
|
|
2020
Q1 | $24.9M | Sell |
447,081
-62,726
| -12% | -$3.83M | 1.52% | 21 |
|
|
2019
Q4 | $32.7M | Sell |
509,807
-36,891
| -7% | -$2.11M | 1.57% | 18 |
|
|
2019
Q3 | $27.7M | Buy |
546,698
+49,455
| +10% | +$2.32M | 1.41% | 30 |
|
|
2019
Q2 | $22.6M | Sell |
497,243
-29,982
| -6% | -$1.4M | 1.11% | 35 |
|
|
2019
Q1 | $25.2M | Buy |
527,225
+24,711
| +5% | +$1.23M | 1.19% | 34 |
|
|
2018
Q4 | $26.1M | Sell |
502,514
-40,622
| -7% | -$2.18M | 1.33% | 30 |
|
|
2018
Q3 | $33.7M | Buy |
+543,136
| New | +$32.2M | 1.38% | 20 |
|
|
2017
Q2 | – | Sell |
-14,333
| Closed | -$779K | – | 273 |
|
|
2017
Q1 | $779K | Sell |
14,333
-10,513
| -42% | -$577K | 0.04% | 220 |
|
|
2016
Q4 | $1.45M | Sell |
24,846
-72,413
| -74% | -$3.96M | 0.07% | 208 |
|
|
2016
Q3 | $5.24M | Sell |
97,259
-264,929
| -73% | -$17M | 0.25% | 87 |
|
|
2016
Q2 | $26.6M | Buy |
362,188
+254,463
| +236% | +$18M | 1.18% | 34 |
|
|
2016
Q1 | $6.88M | Buy |
107,725
+100,675
| +1,428% | +$6.35M | 0.31% | 85 |
|
|
2015
Q4 | $7.05K | Buy |
+7,050
| New | +$466K | 0.34% | 73 |
|
Other funds holding BMY
VCM
VPM
Dana Investment Advisors's BMY Position: Q1 2026 in Review
Dana Investment Advisors reduced its Bristol-Myers Squibb (BMY) stake by 4.4% in Q1 2026, selling an estimated $125K and leaving 46,136 shares worth $2.8M. The position accounts for 0.08% of the portfolio, ranked #259.
Dana Investment Advisors first reported a position in BMY in Q4 2015 and has held it in 34 quarters since. The position peaked at $33.7M in Q3 2018. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Dana Investment Advisors held 46,136 shares of Bristol-Myers Squibb worth $2.8M as of Q1 2026.
- Dana Investment Advisors sold 2,142 Bristol-Myers Squibb shares in Q1 2026, an estimated $125K.
- Bristol-Myers Squibb made up 0.08% of Dana Investment Advisors's portfolio in Q1 2026, its #259 holding.
- Dana Investment Advisors first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 34 quarters since.
- Dana Investment Advisors's Bristol-Myers Squibb position peaked at $33.7M in Q3 2018.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Dana Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.